-

Resaphene Suisse AG: Charité Ethics Committee in Berlin Approves Study on Tinniwell Tinnitus Therapy

ROGGWIL, Switzerland--(BUSINESS WIRE)--The Charité's ethics committee has approved the double-blind study on the tinnitus therapy device tinniwell with Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91. A total of 60 people took part in the study and the head is Prof. Dr. med. Birgit Mazurek commissioned. The results are expected for Q4 / 2020 or Q1 / 2021.

The double-blind study has the same design as a first clinical user observation by Dr. med. Johannes Ebbers. This documented an average relief of 54% within 4 weeks; in one patient the tinnitus was even 100% healed in time. Based on the above facts, Resaphene assumes similar results in the double-blind study. If this is achieved, the tinniwell can become the new global standard in tinnitus therapy. There is currently no known competitor who can deliver comparable therapy results. It is estimated that over 100 million patients are affected in the target markets of Europe and the US.

If the study is successfully completed, the management of Resaphene assumes the participation of further institutional investors or the sale of intellectual property to a hearing aid manufacturer as part of an exit strategy of the previous shareholders. No binding contracts have yet been concluded for this.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016. The shares have been traded on the Vienna Stock Exchange in the Third Market segment since June 2018. Resaphene Deutschland GmbH in Constance and Resaphene UK Ltd. in London and Resaphene US LLC in the US act as further sales companies.

 
 

Language:

English

Company:

Resaphene Suisse AG

Rütistrasse 8b

9325 Roggwil

Switzerland

Phone:

0041714500668

E-mail:

info@resaphene.ch

Internet:

www.resaphene.ch

ISIN:

CH0367465439

Listed:

Foreign Exchange(s) Vienna Stock Exchange

EQS News ID:

957405

 

Contacts

Investor Relations contact:
Mrs. Anke Rauterkus
(Chief Executive Officer)
a.rauterkus@resaphene.ch

Industry:

Resaphene Suisse AG

WBAG:RESA
Release Versions
EnglishGerman

Contacts

Investor Relations contact:
Mrs. Anke Rauterkus
(Chief Executive Officer)
a.rauterkus@resaphene.ch

More News From Resaphene Suisse AG

Resaphene Suisse AG: FDA Approval Process for Tinnitus Therapy Tinniwell Continues

ROGGWIL, Switzerland--(BUSINESS WIRE)--Due to the COVID pandemic, work for the FDA approval of the tinniwell was stopped at the beginning of 2021. This has now been resumed and Chief Medical Officer Thomas Rauterkus has been commissioned to manage the project. The aim is to complete this project within 12 months and thus gain entry into the medical technology market in the USA. We currently assess the market environment as very favorable, since the only serious competitor, Neuralink, led by the...

Resaphene Suisse AG: Tinnitus: 4 Phases Until Healing in the Tailor-Made Notched Music Training (TMNMT) Discovered With Tinniwell

MUNICH--(BUSINESS WIRE)--The studies in the field of tinnitus research are extremely poor. An article in the Medical Tribune Germany dated November 30, 2019 rightly complains that too little research is being done in the area of tinnitus and that patients feel let down by medicine. A particularly bad testimony is given to cognitive behavioral therapy, which is protected by most health insurance companies. In the hope that the sound disappears, this therapy only teaches how to deal with everyday...
Back to Newsroom